Biotage and Peptide Synthesis
News May 14, 2013
CEM Corporation has recently published a press release claiming to have won a “patent dispute” with Biotage. The so called “patent dispute” relates to Biotage’s filing of opposition against certain patents of CEM in Europe (Germany, France, Italy and Great Britain) and Japan, because Biotage believes that the patents as originally granted give CEM a broader protection than CEM is entitled to.
In April 2013 the Japanese Patent Office found that CEM’s patent, relating to microwave assisted solid phase peptide synthesis, is invalid.
Also the European Patent Office found that the scope of the corresponding European patent should be restricted.
The decisions by both patent offices were taken in response to the requests filed by Biotage. The decisions are open to appeal by both parties.
Biotage’s instruments for microwave assisted organic chemistry have been used in the scientific community since the late 1990s. Scientists took advantage of these early Biotage instruments to carry out microwave-assisted peptide synthesis more than ten years ago, even before CEM filed their first patent application in this field.
As early as in 2002, Professor Gogoll and his team at Uppsala University published an article entitled “Rapid Microwave-Assisted Solid Phase Peptide Synthesis” using a Biotage instrument.
This is part of Biotage’s heritage in the peptide synthesis business, which led the company to put more dedicated efforts into the peptide synthesis area, culminating in the launch of the Biotage® Syro Wave™ in 2010.
In 2012 Biotage launched the successful Biotage® Initiator+ Alstra™, which is the company’s latest automated microwave peptide synthesizer.
“Biotage of course respects third party patent rights. I am surprised that CEM claims that we are in a dispute and even more that they claim to have won. This is an ongoing discussion on what the fair scope of these patents is, if any. The CEM patents concerned do not cover Biotage’s line of instruments for microwave assisted peptide synthesis. All synthesis protocols preinstalled in the Biotage instruments are outside the patents, even as originally granted. The situation is the same with the corresponding US patents. This means that customers all over the world can continue to use Biotage’s microwave peptide synthesizers with the preinstalled methods. Peptide synthesis is a product area where Biotage will continue to grow and deliver exciting products to the market.” says Torben Jörgensen, CEO of Biotage.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE